BUZZ-Lumexa shares rise after Truist gives "Buy" rating
路透社2026/10/05 12:21On October 5th, shares of diagnostic equipment supplier Lumexa Imaging (LMRI.O) rose 2% in pre-market trading to $10.6. Brokerage Truist Securities initiated coverage with a “Buy” rating and a target price of $18, which implies about 74% upside from the previous trading day’s close. The company offers diagnostic imaging services, including MRI, CT, and PET scans, as well as X-ray, ultrasound, and mammography services. All five brokerages currently covering LMRI have assigned it a “Buy” or higher rating, with a median target price of $17.50, according to data compiled by LSEG. As of the previous close, LMRI’s share price has declined 44.22% year-to-date. (For non-English speakers, Reuters automatically translates its reports into several languages. Due to the possibility of errors or missing context in automated translations, Reuters does not guarantee their accuracy and provides these translations solely for reader convenience. Reuters accepts no liability for any damage or loss arising from the use of automated translation.)
October 5 - ** Shares of diagnostic equipment supplier Lumexa Imaging (LMRI.O) rose 2% in pre-market trading, at $10.6.
** Brokerage Truist Securities initiated coverage (link), with a "Buy" rating and a target price of $18.
** This target price suggests an upside of about 74% compared to the previous trading day's closing price.
** The company offers diagnostic imaging services, including MRI, CT and PET scans, as well as X-ray, ultrasound and mammography services.
** All 5 brokerages currently covering this stock rate LMRI as "Buy" or above; their median target price is $17.50 — LSEG compiled data.
** As of the previous trading day’s close, LMRI shares had fallen 44.22% year-to-date.
(To assist non-native English speakers, Reuters has automatically translated its report into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for readers’ convenience. Reuters accepts no liability for any damage or loss arising from the use of automated translation features.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BitMine Shares Outperformed Ethereum in 2026, and Tom Lee Highlights One Move
Doosan Heavy Industries shipped its first gas turbine to SpaceXAI.
WTI Price Forecast: Bulls seem hesitant near $89.00 amid easing supply risks
BUZZ - India's Kotak Mahindra Bank shares rise on second quarter loan growth; Goldman Sachs reiterates 'Buy' rating
October 6 – ** Shares of India’s Kotak Mahindra Bank KTKM.NS rose 3.3% to 429.80 rupees ** Kotak Mahindra Bank reported a 24.7% increase in net loans for Q2 FY2027 (link) ** Goldman Sachs reiterated its “Buy” rating with a target price of 540 rupees, citing the better-than-expected Q2 performance update ** Given strong deposit growth and organic loan expansion, the bank’s EPS compound annual growth rate (CAGR) estimate for FY2026-29 was raised to 19% ** It was noted that organic loan growth rose from 15% in the previous quarter to 19% year-on-year; this growth momentum is expected to continue, supported by retail loans, SME lending, and commercial banking ** An average of 37 analysts give the stock a “Buy” rating, with a median target price of 470 rupees – data compiled by LSEG ** Year-to-date, the stock is down 5.5% (To assist non-English speakers, Reuters automatically translates its reports into several other languages. Due to the possibility of errors or lack of required context in automated translations, Reuters does not guarantee their accuracy and provides them for convenience only. Reuters accepts no liability for any damage or loss resulting from the use of automated translation features.)
Crypto prices
More
